We are live on ! Find out more
RVLP

RVL Pharmaceuticals plc Ordinary Shares
RVLP

Delisted

RVLP was delisted on the 20th of October, 2023.

Back to rankings

3 hedge funds and large institutions have $613 invested in RVL Pharmaceuticals plc Ordinary Shares in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 31 closing their positions.

New
Increased
Maintained
Reduced
Closed

91% less funds holding

Funds holding: 32 → 3 (-29)

94% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 31

100% less capital invested

Capital invested by funds: $1.57M → $613 (-$1.57M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
3
Holders Change
-29
Holders Change %
-90.63%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
2
Increased
1
Reduced
–
Closed
31
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
XT
XTX Topco
Cayman Islands
+$17.9K
2
RJA
Raymond James & Associates
Florida
+$2.35K
3
Simplex Trading
Simplex Trading
Illinois
+$523

Top Sellers

Rank Fund Capital Flow
1
ACM
Athyrium Capital Management
New York
-$1.26M
2
Renaissance Technologies
Renaissance Technologies
New York
-$93K
3
Blackstone Inc
Blackstone Inc
New York
-$56.9K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$26.6K
5
Millennium Management
Millennium Management
New York
-$23.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
XT
1
XTX Topco
Cayman Islands
$542 +$17.9K +180,566 New
RJA
2
Raymond James & Associates
Florida
$71 +$2.35K +23,696 New
ACM
3
Athyrium Capital Management
New York
– -$1.26M -14,600,444 Closed
Renaissance Technologies
4
Renaissance Technologies
New York
– -$93K -1,079,515 Closed
Blackstone Inc
5
Blackstone Inc
New York
– -$56.9K -632,264 Closed
Geode Capital Management
6
Geode Capital Management
Massachusetts
– -$26.6K -307,266 Closed
Millennium Management
7
Millennium Management
New York
– -$23.6K -272,584 Closed
Vanguard Group
8
Vanguard Group
Pennsylvania
– -$21.3K -246,353 Closed
BlackRock
9
BlackRock
New York
– -$19.5K -225,727 Closed
State Street
10
State Street
Massachusetts
– -$9.22K -106,487 Closed
RJFSA
11
Raymond James Financial Services Advisors
Florida
– -$8.92K -103,037 Closed
TAM
12
Titleist Asset Management
Texas
– -$8.67K -100,142 Closed
IA
13
Insight Advisors
Pennsylvania
– -$6.55K -75,646 Closed
Northern Trust
14
Northern Trust
Illinois
– -$5.66K -65,334 Closed
CSS
15
Cubist Systematic Strategies
Connecticut
– -$4.21K -48,558 Closed
TRCT
16
Tower Research Capital (TRC)
New York
– -$2.86K -32,898 Closed
Morgan Stanley
17
Morgan Stanley
New York
– -$2.77K -32,000 Closed
HF
18
HRT Financial
New York
– -$2K -31,688 Closed
Susquehanna International Group
19
Susquehanna International Group
Pennsylvania
– -$2.69K -31,006 Closed
CF
20
Cantor Fitzgerald
New York
– -$1.92K -22,181 Closed
LPL Financial
21
LPL Financial
California
– -$1.84K -21,210 Closed
UBS Group
22
UBS Group
Switzerland
– -$1.37K -15,708 Closed
Wells Fargo
23
Wells Fargo
California
– -$1.32K -15,246 Closed
Bank of New York Mellon
24
Bank of New York Mellon
New York
– -$1.05K -12,078 Closed
WJWM
25
Williams Jones Wealth Management
New York
– -$866 -10,000 Closed
1
2

RVLP Hedge Fund Activity: Q4 2023 in Review

3 of the 6,860 institutional investors tracked by Wall St. Rank reported a position in RVL Pharmaceuticals plc Ordinary Shares (RVLP) for Q4 2023, worth a combined $613 — down 100% from $1.57M a quarter earlier.

Sellers outnumbered buyers: 31 funds closed out of RVLP and 2 opened new positions — a net loss of 29 holders — while 0 trimmed existing stakes and 1 added.

The largest buyer was XTX Topco, opening a new position worth an estimated $17.9K. The largest seller was Athyrium Capital Management, exiting entirely with an estimated $1.26M sold.

  • 3 institutional investors held RVL Pharmaceuticals plc Ordinary Shares (RVLP) as of Q4 2023, down from 32 in Q3 2023.
  • Funds reported $613 of RVL Pharmaceuticals plc Ordinary Shares stock for Q4 2023, down 100% quarter-over-quarter.
  • 2 funds opened new RVL Pharmaceuticals plc Ordinary Shares positions in Q4 2023 and 31 closed out, a net change of -29 holders.
  • The largest RVL Pharmaceuticals plc Ordinary Shares buyer in Q4 2023 was XTX Topco, an estimated $17.9K added.
  • The largest RVL Pharmaceuticals plc Ordinary Shares seller in Q4 2023 was Athyrium Capital Management, an estimated $1.26M sold.

Based on aggregated 13F filings for Q4 2023.